GE to sell MPI stress agent in Europe

GE Healthcare has signed an agreement with Rapidscan Pharma Solutions to sell that company's pharmacological stress agent for myocardial perfusion imaging (MPI) studies in Europe.

GE will sell the Rapiscan (regadenoson) coronary vasodilator in the U.K. and Germany. Rapiscan is a selective A2A adenosine receptor agonist designed for adult patients unable to undergo adequate exercise stress testing in the diagnosis of coronary artery disease.

Page 1 of 1244
Next Page